SORT BY

The Future 50

Courtesy of Edwards Lifesciences
leaders

7

Edwards Lifesciences

EW

Edwards Lifesciences’ Sapien 3 artificial heart valve, implanted through a catheter, is an alternative for heart disease patients whose conditions are bad enough to make surgery too risky. Over the past two years it’s been FDA approved for an increasing number of procedure types, including for repairing existing artificial valves that are breaking down. The com­pany’s growing footprint globally has driven strong sales abroad, where these kinds of minimally invasive heart procedures are becoming more popular. Edwards has been able to maintain at least a 24% net profit margin through the first half of 2017.

Looking for leads, investment insights, or competitive intelligence?

Overall Score

2.7

Sector

Health Care

Industry

Medical Products and Equipment

CEO

Michael A. Mussallem

Employees

11,100

HQ Location

Irvine, Calif.

Revenues ($M) (Past 12 Months)

$3,232

Profits ($M) (Past 12 Months)

$716

Market Value as of Oct. 9, 2017 ($M)

$23,274

Revenue and net income for 12 months ended June 30, 2017. Source: S&P Global.
Edwards Lifesciences is also featured in these fortune lists

News about Edwards Lifesciences

Why Edwards Lifesciences Surged to an All-Time High Today

Solid heart procedure trial results sent shares soaring 17%.

Read More →